ARS Pharmaceuticals, Inc. Common Stock (SPRY)

Price$9.43

Value ScoreD

Growth ScoreB

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)18.84%

Price vs S&P 500 (4W)0.99%

VGM Score48.60

Market Capitalization$900.68M

P/E Ratio (Annual)102.30x

All Metrics

P/CF (Annual)60.39x

Book Value / Share (Quarterly)$0.62

P/TBV (Annual)11.54x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)299.68%

Cash Flow / Share (Quarterly)$-1.77

Price vs S&P 500 (YTD)-33.08%

Gross Margin (TTM)74.12%

Net Profit Margin (TTM)-200.00%

EPS (TTM)$-2.00

10-Day Avg Trading Volume2.03M

EPS Excl Extra (TTM)$-2.00

EPS (Annual)$-1.74

ROI (Annual)-81.33%

Gross Margin (Annual)76.72%

Cash / Share (Quarterly)$2.02

Revenue Growth QoQ (YoY)184.47%

P/E Normalized (Annual)102.30x

ROA (Last FY)-52.28%

Revenue Growth TTM (YoY)1.92%

EBITD / Share (TTM)$-2.03

ROE (5Y Avg)-42.32%

Operating Margin (TTM)-204.49%

Cash Flow / Share (Annual)$-1.72

P/B Ratio14.69x

P/B Ratio (Quarterly)13.01x

Net Income / Employee (Annual)$-1,084,200

EV / Revenue (TTM)9.83x

Net Interest Coverage (TTM)-64.94x

ROA (TTM)-60.85%

EV / EBITDA (TTM)102.89x

EPS Incl Extra (Annual)$-1.74

Current Ratio (Annual)7.28x

Quick Ratio (Quarterly)4.63x

3-Month Avg Trading Volume1.53M

52-Week Price Return-41.45%

EV / Free Cash Flow (Annual)65.84x

Revenue / Employee (TTM)$626,500

Tangible BV / Share (Quarterly)$0.47

P/S Ratio (Annual)10.69x

Asset Turnover (Annual)0.26x

52-Week High$18.90

EPS Excl Extra (Annual)$-1.74

CapEx CAGR (5Y)-18.10%

26-Week Price Return34.77%

Quick Ratio (Annual)6.91x

13-Week Price Return-2.89%

Total Debt / Equity (Annual)0.84x

Current Ratio (Quarterly)4.94x

Enterprise Value$972.88M

Asset Turnover (TTM)0.30x

Revenue / Employee (Annual)$533,400

Pretax Margin (Annual)-203.35%

Cash / Share (Annual)$2.47

3-Month Return Std Dev58.92%

Net Income / Employee (TTM)$-1,253,000

ROE (Last FY)-149.92%

Net Interest Coverage (Annual)-19.24x

EPS Basic Excl Extra (Annual)$-1.74

Receivables Turnover (TTM)5.21x

Total Debt / Equity (Quarterly)1.57x

EPS Incl Extra (TTM)$-2.00

ROI (TTM)-98.41%

P/S Ratio (TTM)9.10x

Revenue / Share (Annual)$0.85

Tangible BV / Share (Annual)$1.01

Price vs S&P 500 (52W)-69.65%

Year-to-Date Return-22.15%

5-Day Price Return14.23%

EPS Normalized (Annual)$-1.74

ROA (5Y Avg)-22.49%

Net Profit Margin (Annual)-203.25%

Month-to-Date Return9.81%

Cash Flow / Share (TTM)$-0.24

EBITD / Share (Annual)$-1.81

Operating Margin (Annual)-212.92%

LT Debt / Equity (Annual)0.84x

ROI (5Y Avg)-28.60%

LT Debt / Equity (Quarterly)1.57x

EPS Basic Excl Extra (TTM)$-2.00

P/TBV (Quarterly)16.92x

P/B Ratio (Annual)10.08x

Inventory Turnover (TTM)3.18x

Pretax Margin (TTM)-200.08%

Book Value / Share (Annual)$1.15

Price vs S&P 500 (13W)-12.64%

Beta0.93x

P/FCF (Annual)69.36x

Revenue / Share (TTM)$1.00

ROE (TTM)-153.61%

52-Week Low$6.66

vGradeD

gGradeB

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.61est. -0.54

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.42

4.38

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
SPRYARS Pharmaceuticals, Inc. Common Stock	D	B	C	$9.43
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

ARS Pharmaceuticals commercializes Neffy, a needle-free intranasal epinephrine treatment for Type 1 allergic reactions and anaphylaxis. The proprietary formulation combines epinephrine with an absorption enhancer to deliver efficacy comparable to injectable alternatives. Neffy is marketed globally under different trade names, including EURneffy in the European Union and United Kingdom.